{"filing":{"accession_number":"0001295947-26-000040","cik":"0001295947","ticker":"PBH","company_name":"Prestige Consumer Healthcare Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"pbh-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1295947/000129594726000040/pbh-20260806.htm"},"events":[{"id":25700,"run_id":23323,"accession_number":"0001295947-26-000040","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"Prestige Consumer Healthcare disclosed Q1 fiscal 2027 financial results (quarter ended June 30, 2026) with revenue of $265.7 million (up 6.5% YoY), diluted EPS of $0.61, and adjusted diluted EPS of $0.98. The company raised its full-year fiscal 2027 guidance to revenue of $1,290–$1,315 million and adjusted diluted EPS of $4.55–$4.65, reflecting the recently closed Breathe Right and LaCorium acquisitions.","company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26597,"accession_number":"0001295947-26-000040","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"The filing discloses Prestige Consumer Healthcare's financial results for the fiscal quarter ended June 30, 2026, with a press release attached as Exhibit 99.1. The disclosure includes Q1 revenue of $265.7 million (up 6.5% YoY), diluted EPS of $0.61, adjusted diluted EPS of $0.98, and updated fiscal 2027 guidance raising revenue outlook to $1,290–$1,315 million and adjusted diluted EPS to $4.55–$4.65. This is a standard quarterly earnings announcement material to investors' assessment of the company's financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:23:50.749606+00:00","company_name":"","ticker":null,"filing_date":""},{"id":26598,"accession_number":"0001295947-26-000040","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure furnishes an investor presentation regarding the Company's financial results for Q1 fiscal 2027 ended June 30, 2026, with the earnings release (Exhibit 99.1) showing Q1 revenue of $265.7 million (up 6.5%), diluted EPS of $0.61, and adjusted diluted EPS of $0.98. The filing explicitly references the earnings release and investor presentation as the primary disclosures, and the company raised its full-year fiscal 2027 outlook to $1,290–$1,315 million revenue and $4.55–$4.65 adjusted diluted EPS, reflecting the recently closed Breathe Right and LaCorium acquisitions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:23:50.749606+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26597,"accession_number":"0001295947-26-000040","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"The filing discloses Prestige Consumer Healthcare's financial results for the fiscal quarter ended June 30, 2026, with a press release attached as Exhibit 99.1. The disclosure includes Q1 revenue of $265.7 million (up 6.5% YoY), diluted EPS of $0.61, adjusted diluted EPS of $0.98, and updated fiscal 2027 guidance raising revenue outlook to $1,290–$1,315 million and adjusted diluted EPS to $4.55–$4.65. This is a standard quarterly earnings announcement material to investors' assessment of the company's financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:23:50.749606+00:00","company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","filing_date":"2026-08-06"},{"id":26598,"accession_number":"0001295947-26-000040","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure furnishes an investor presentation regarding the Company's financial results for Q1 fiscal 2027 ended June 30, 2026, with the earnings release (Exhibit 99.1) showing Q1 revenue of $265.7 million (up 6.5%), diluted EPS of $0.61, and adjusted diluted EPS of $0.98. The filing explicitly references the earnings release and investor presentation as the primary disclosures, and the company raised its full-year fiscal 2027 outlook to $1,290–$1,315 million revenue and $4.55–$4.65 adjusted diluted EPS, reflecting the recently closed Breathe Right and LaCorium acquisitions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:23:50.749606+00:00","company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","filing_date":"2026-08-06"}]}